Patrono Damiano, Lupo Francesco, Canta Francesca, Mazza Elena, Mirabella Stefano, Corcione Silvia, Tandoi Francesco, De Rosa Francesco Giuseppe, Romagnoli Renato
General Surgery 2U - Liver Transplant Unit, University of Torino, A.O.U. Città della Salute e della Scienza, Torino, Italy.
Department of Medical Sciences, Infectious Diseases, University of Torino, A.O.U. Città della Salute e della Scienza, Torino, Italy.
Transpl Infect Dis. 2020 Oct;22(5):e13353. doi: 10.1111/tid.13353. Epub 2020 Jun 16.
Covid-19 pandemic is deeply affecting transplant activity worldwide. It is unclear whether solid organ transplant recipients are at increased risk of developing severe complications and how they should be managed, also concerning immunosuppression. This is a report about the course and management of SARS-CoV-2 infection in liver transplant recipients from a single center in Northwestern Italy in the period March-April 2020. Three patients who were treated at our institution are reported in detail, whereas summary data are provided for those managed at peripheral Hospitals. Presentation varied from asymptomatic to rapidly progressive respiratory failure due to bilateral interstitial pneumonia. Accordingly, treatment and changes to immunosuppression were adapted to the severity of the disease. Overall mortality was 20%, whereas Covid-related mortality was 10%. Two cases of prolonged (>2 months) viral carriage were observed in two asymptomatic patients who contracted the infection in the early course after transplant. Besides depicting Covid-19 course and possible treatment scenarios in liver transplant patients, these cases are discussed in relation to the changes in our practice prompted by Covid-19 epidemic, with potential implications for other transplant programs.
新冠疫情正在深刻影响全球的移植活动。实体器官移植受者发生严重并发症的风险是否增加,以及应如何对他们进行管理(包括免疫抑制方面)尚不清楚。这是一份关于2020年3月至4月期间意大利西北部一个中心肝移植受者感染新型冠状病毒肺炎(SARS-CoV-2)的病程及管理情况的报告。详细报告了在我们机构接受治疗的3例患者,同时提供了在外围医院接受管理患者的汇总数据。临床表现从无症状到因双侧间质性肺炎导致的快速进展性呼吸衰竭不等。相应地,治疗及免疫抑制调整根据疾病严重程度进行。总体死亡率为20%,而新冠相关死亡率为10%。在两名移植后早期感染的无症状患者中观察到两例病毒携带时间延长(>2个月)的情况。除了描述肝移植患者的新冠病程及可能的治疗方案外,还结合新冠疫情促使我们实践发生的变化对这些病例进行了讨论,这可能对其他移植项目产生影响。